KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Goodwill & Intangibles (2018 - 2025)

Castle Biosciences' Goodwill & Intangibles history spans 5 years, with the latest figure at $99.6 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 6.26% year-over-year to $99.6 million; the TTM value through Dec 2025 reached $99.6 million, down 6.26%, while the annual FY2025 figure was $99.6 million, 6.26% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $99.6 million at Castle Biosciences, down from $101.8 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $132.7 million in Q2 2022 and bottomed at $77.9 million in Q1 2025.
  • The 5-year median for Goodwill & Intangibles is $114.0 million (2024), against an average of $111.8 million.
  • The largest annual shift saw Goodwill & Intangibles skyrocketed 42.09% in 2022 before it crashed 32.31% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $88.9 million in 2021, then surged by 42.09% to $126.3 million in 2022, then fell by 7.13% to $117.3 million in 2023, then decreased by 9.47% to $106.2 million in 2024, then fell by 6.26% to $99.6 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Goodwill & Intangibles are $99.6 million (Q4 2025), $101.8 million (Q3 2025), and $104.1 million (Q2 2025).